Novavax (NVAX) reached $8.48 at the closing of the latest trading day, reflecting a -4.83% change compared to its last close.

If you have been tracking Novavax, you know it is the kind of stock that makes you wonder whether to hold on, cut losses, or set up for a comeback. Over the last month, the stock has climbed a sturdy ...

It’s that time of year when the leaves are turning golden, there’s a chill in the air and the threat of respiratory viruses ...

Himanshu Shah, managing partner and chief investment officer at Shah Capital, slammed Novavax management, and said the company should sell itself.

AstraZeneca followed the blueprint of a deal Pfizer recently cut with the White House. Elsewhere, Novo is shuttering its cell ...

One of Novavax’s largest shareholders is again putting pressure on the Gaithersburg vaccine maker — this time, to consider a ...

A troubled Indiana contract manufacturing plant recently acquired by Novo Nordisk is considered to not be in compliance with ...

Novavax (NVAX) shares traded 1% higher in the pre-market session on Tuesday after its second-largest shareholder, Shah ...

Novavax Inc said on Monday it was on track to begin a delayed U.S.-based, late-stage study of its experimental coronavirus vaccine later this month.

U.S. drug developer Novavax Inc said on Tuesday it was doubling its potential COVID-19 vaccine manufacturing capacity to two billion doses annually under an agreement with Serum Institute of India, ...

Novavax (NVAX) ended the recent trading session at $8.68, demonstrating a -2.2% change from the preceding day's closing price. This change lagged the S&P 500's 0.55% loss on the day. At the same time, ...

The Food and Drug Administration recently put new restrictions on this year’s shots from Pfizer, Moderna and Novavax, reserving them for people over 65 or younger ones who are deemed at higher risk ...